Medical Condition News

RSS

Special glasses to spot people at risk for PTSD

Around 30 percent of people surviving a traumatic event, such as a serious car crash, will go on to develop Post Traumatic Stress Disorder (PTSD). Doctors don't know who is susceptible and treating people who don't have PTSD can make things worse. However, new research by psychologist Dr Peter Naish, of the Open University, and his colleague Dr Ksenja da Silva, may help.

18 Nov 2010

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

In a study published today in the International Journal of Cancer, Gen-Probe's APTIMA HPV Assay provided a better combination of sensitivity and specificity than HPV DNA- or cytology-based tests for cervical cancer screening.

18 Nov 2010

Sun Pharma receives FDA approval for generic Tiazac ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac® extended release capsules.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

FDA approves Sun Pharma's generic Clarinex ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted it an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Schering Plough's Clarinex® tablets, 5 mg.

18 Nov 2010

LVNC cardiomyopathy associated with heart failure, stroke and ventricular arrhythmias

Left ventricular non-compaction (LVNC), a cardiomyopathy about which little is fully understood, is associated with heart failure (HF), stroke and ventricular arrhythmias, according to a study to be presented Nov. 17 at the 2010 American Heart Association (AHA) Scientific Sessions in Chicago. The researchers also will report that advanced imaging technologies reveal that developing these cardiac risks appear to progress over time in patients with LVNC.

18 Nov 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied.

18 Nov 2010

Beams of light advance prosthetic limbs

Using beams of light to allow amputees not only to control but also to feel the movement of prosthetic limbs is the ambitious goal of a new $5.6 million Department of Defense initiative.

18 Nov 2010

Cardiac stem cells from sick patients could generate new heart muscle: Research

Cardiac stem cells even in elderly and sick patients could generate new heart muscle and vessel tissue and be used to treat heart failure, according to research presented at the American Heart Association's Scientific Sessions 2010.

18 Nov 2010

Access Pharmaceuticals to present two oncology posters at CPR Conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.

18 Nov 2010

Researchers find clue behind dementia development

Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.

18 Nov 2010

New technique to identify cancer biomarkers

The University of Liège has presented TARGETOME, the most recent of its spin-offs, which is also the first to spring from its applied geno-proteomics centre, GIGA.

18 Nov 2010

Multiple pain locations contribute to greater knee pain

A new study found that patients with osteoarthritis (OA) of the knee who also have pain in other joints were more likely to experience greater knee pain. Specifically, pain in the lower back as well as foot pain and elbow pain on the same side as the affected knee were associated with more severe knee pain. Full details appear in the December issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

Cell Therapeutics, Inc. announced today that CTI's Marketing Authorization Application seeking approval for Pixuvri (pixantrone dimaleate) for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma was validated and accepted for review by the European Medicines Agency.

18 Nov 2010

Cigarette smoke, automobile exhaust and french fries increase risk of developing Alzheimer's disease

There is growing evidence that exposure to a group of chemicals known as type-2 alkenes -- which are found in the smoke inhaled from cigarettes, the exhaust of automobiles and even in French fries - can increase the chances of developing Alzheimer's disease and other neurological conditions such as Parkinson's disease.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.

18 Nov 2010

Medical Condition News

Special glasses to spot people at risk for PTSD

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

Sun Pharma receives FDA approval for generic Tiazac ANDA

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

FDA approves Sun Pharma's generic Clarinex ANDA

LVNC cardiomyopathy associated with heart failure, stroke and ventricular arrhythmias

Researchers report results from Phase III DEFINE study for coronary heart disease

Beams of light advance prosthetic limbs

Cardiac stem cells from sick patients could generate new heart muscle: Research

Access Pharmaceuticals to present two oncology posters at CPR Conference

Researchers find clue behind dementia development

New technique to identify cancer biomarkers

Multiple pain locations contribute to greater knee pain

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

Cigarette smoke, automobile exhaust and french fries increase risk of developing Alzheimer's disease

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News